BRPI0803085A2 - forma triol de rosuvastatina - Google Patents

forma triol de rosuvastatina Download PDF

Info

Publication number
BRPI0803085A2
BRPI0803085A2 BRPI0803085-5A BRPI0803085A BRPI0803085A2 BR PI0803085 A2 BRPI0803085 A2 BR PI0803085A2 BR PI0803085 A BRPI0803085 A BR PI0803085A BR PI0803085 A2 BRPI0803085 A2 BR PI0803085A2
Authority
BR
Brazil
Prior art keywords
rosuvastatin triol
rosuvastatin
triol form
triol
rosuvastatina
Prior art date
Application number
BRPI0803085-5A
Other languages
English (en)
Inventor
Valerie Niddam-Hildesheim
Anna Balanov
Irena Veinberg
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0803085A2 publication Critical patent/BRPI0803085A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

FORMA TRIOL DE ROSUVASTATINA. Provê-se um triol de rosuvastatina e seu uso como um padrão de referência para análise da rosuvastatina.
BRPI0803085-5A 2007-03-13 2008-03-13 forma triol de rosuvastatina BRPI0803085A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90691407P 2007-03-13 2007-03-13
US91846607P 2007-03-15 2007-03-15
PCT/US2008/003470 WO2008112317A2 (en) 2007-03-13 2008-03-13 Triol form of rosuvastatin

Publications (1)

Publication Number Publication Date
BRPI0803085A2 true BRPI0803085A2 (pt) 2011-08-30

Family

ID=39650560

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0803085-5A BRPI0803085A2 (pt) 2007-03-13 2008-03-13 forma triol de rosuvastatina

Country Status (8)

Country Link
EP (1) EP2121631A2 (pt)
JP (1) JP5330225B2 (pt)
KR (1) KR100945760B1 (pt)
BR (1) BRPI0803085A2 (pt)
CA (1) CA2680604C (pt)
IL (1) IL200449A0 (pt)
MX (1) MX2008014552A (pt)
WO (1) WO2008112317A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154015A1 (en) * 2010-06-07 2011-12-15 Pharmathen S.A. Improved process for the preparation of propenal intermediate and derivatives thereof
CN112782333B (zh) * 2020-12-25 2022-07-12 石家庄四药有限公司 一种匹伐他汀异丙基叔丁酯非对映异构体的hplc检测方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1894221B (zh) * 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品

Also Published As

Publication number Publication date
KR20090010195A (ko) 2009-01-29
IL200449A0 (en) 2010-04-29
MX2008014552A (es) 2009-03-09
KR100945760B1 (ko) 2010-03-08
WO2008112317A2 (en) 2008-09-18
EP2121631A2 (en) 2009-11-25
JP5330225B2 (ja) 2013-10-30
CA2680604C (en) 2012-08-07
JP2009519353A (ja) 2009-05-14
WO2008112317A3 (en) 2008-11-06
CA2680604A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
ES2570569T3 (es) Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
BRPI0907435A8 (pt) derivados de 5-flúor pirimidina
CO6731068A2 (es) Arilpirrolodonas pesticidas
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
ECSP088961A (es) Nuevos herbicidas
BRPI1014572A2 (pt) imidazoprazinas para uso como inibidores de cinase
UY31038A1 (es) Compuestos
BR112012004970A2 (pt) inibidores de jak2 e seu uso para o tratamento de doenças mieloproliferativas e câncer
BRPI1014708A2 (pt) dihidropirimidinonas para uso como inibidores de bace2
ECSP14027269A (es) Picolinamidas macrocíclicas como fungicidas
ECSP14033037A (es) Síntesis de compuestos heterocíclicos
HN2012000263A (es) Derivados n1-sulfonil-5-fluoropirimidinona
BRPI0906444A2 (pt) Compostos de 4-piridinona e seu uso para câncer
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
UY35762A (es) Uso de picolinamidas macrocíclicas como fungicidas
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
BR112012001797A2 (pt) composto bicíclico e uso do mesmo para propósitos médicos
BR112012008044A2 (pt) pteridinas e seu uso como agroquímicos
BRPI0810882A2 (pt) Derivados de ftalazinona e seu uso como medicamento para tratar câncer
BRPI1015367A2 (pt) imidazotiodiazois para uso como inibidores de cinase
HN2010001614A (es) Confitura
BRPI0814231A2 (pt) Derivados de pleuromutilina e seu uso como antimicrobianos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A E 4A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 3A E 4A ANUIDADES.